Vertaling van "optimal scenario for informing the patient with regard " (Nederlands → Frans) :

The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but (Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”. Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken.
The optimal scenario for informing the patient with regard to decisions related to reimbursement of products linked to a specific treatment is similar to the previous one but ( Figure 8) presents a higher number of respondents choosing “inside the organs” and “at each step”.

In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.
Only 26% would choose to inform the patient outside the existing organs, and with a stronger preference on informing after the decision is taken. In the first scenario, there is no significant difference between the respondents with regard to the choice of the place where the information is given (inside or outside the existing decision-making organs) according their current/past membership (or not) of the INAMI – RIZIV organs.

The subpoena covered information regarding potential off-label marketing and promotion of TOBI, a treatment for patients with cystic fibrosis acquired through the purchase of Chiron Corporation in mid-2006.
Cette assignation couvrait des informations concernant l’éventualité d’une commercialisation et de promotion de TOBI, un traitement contre la fibrose cystique acquis lors de l'achat de Chiron Corporation à la mi-2006, pour des indications pour lesquelles ce produit n’a pas été autorisé.

The subpoena covered information regarding potential off-label marketing and promotion of TOBI (tobramycin), a treatment for patients with cystic fibrosis acquired through the purchase of Chiron Corporation in mid-2006.
Cette assignation couvrait des informations concernant l’éventualité d’une commercialisation et de promotion de TOBI (tobramycine), un traitement contre la fibrose cystique acquis lors de l’achat de Chiron Corporation à la mi-2006, pour des indications pour lesquelles ce produit n’a pas été autorisé.